DOCSLIB.ORG

The Relationship Between ADAMTS13 Genotype and Phenotype in Congenital Thrombotic Thrombocytopenic Purpura and Characterisation of ADAMTS13 Mutants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The relationship between ADAMTS13 genotype and phenotype in congenital thrombotic thrombocytopenic purpura and characterisation of ADAMTS13 mutants Mary Imy Underwood Thesis submitted to University College London for the degree of Doctor of Philosophy University College London 2015 1 I, Mary Imy Underwood confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. …………………………………………………. 2 Abstract Congenital thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy, usually involving ADAMTS13 gene defects. ADAMTS13 processes the multimeric plasma glycoprotein Von Willebrand factor making it less reactive to platelets. Patients differ in terms of disease severity and evidence suggests a relationship between ADAMTS13 genotype and disease phenotype. Over 140 mutations have been identified in patients but only ~30% of these has been expressed in vitro. The aim of this thesis was to study certain ADAMTS13 mutations identified in a homozygous form in congenital TTP patients to assess in vitro their effect on the secretion and activity of ADAMTS13 and to assess their contribution to disease phenotype. ADAMTS13 mutants (p.R102H, p.I143T and p.Y570C) and wild type (WT) were expressed in HEK293T cells. The p.R102H mutation partially affected the secretion of ADAMTS13 and reduced the catalytic efficiency of the mutant but not to the extent predicted based upon levels measured in patient plasma. Expressing this mutant with three ADAMTS13 polymorphisms (p.Q448E, p.P618A and p.A900V) which were also identified in the patient with this mutation further reduced the secretion and activity of ADAMTS13. When these three polymorphisms were expressed separately in WT ADAMTS13, the p.P618A polymorphism reduced the secretion and subsequently the activity of ADAMTS13 suggesting that this polymorphism in particular was responsible for the reduction observed. These results highlight the importance of ADAMTS13 polymorphisms. The p.I143T and p.Y570C mutations severely affected ADAMTS13 secretion. Immunofluorescence studies showed localisation of these mutants within the ER but less extensive localisation within the cis Golgi compared to WT ADAMTS13. The p.I143T mutant was characterised further and was shown to be degraded by the cell proteasome. Addition of a chemical chaperone (betaine) appeared to rescue the secretion defect caused by the p.I143T mutation. This may have future therapeutic implications for the treatment of some congenital TTP patients. 3 Acknowledgements I would like to thank my supervisors Dr. Ian Mackie, Professor Samuel Machin and Professor Flora Peyvandi for their help and support throughout the last four years. I also would like to thank all staff at the Haemostasis Research Unit in UCL and the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan, in particular Dr. Isabella Garagiola. I would also like to thank Dr. Raimondo De Cristofaro, Dr. Stefano Lancelloti, Mr George Chennel and Mr Tomas Adejumo for their technical support. Finally I would like to thank my family for their support throughout. 4 Contents Abstract ...................................................................................................................... 3 Acknowledgements .................................................................................................... 4 Chapter 1 Introduction ........................................................................................ 21 1.1 Von Willebrand Factor ............................................................................ 21 1.1.1 VWF gene, synthesis, secretion ......................................................... 21 1.1.2 VWF function .................................................................................... 22 1.1.3 ADAMTS13 regulates the size of VWF ............................................ 25 1.2 The ADAMTS13 gene, synthesis and secretion ....................................... 27 1.2.1 Gene ................................................................................................... 27 1.2.2 Synthesis ............................................................................................ 28 1.2.3 Secretion ............................................................................................ 28 1.3 The ADAMTS13 protein......................................................................... 29 1.3.1 The ADAMTS family ........................................................................ 29 1.3.2 ADAMTS13 ....................................................................................... 30 1.3.3 Propeptide .......................................................................................... 31 1.3.4 Metalloprotease domain ..................................................................... 31 1.3.5 Disintegrin-like domain ..................................................................... 32 1.3.6 TSP-1 domain .................................................................................... 33 1.3.7 Cysteine-rich domain ......................................................................... 34 1.3.8 Spacer domain .................................................................................... 34 1.3.9 TSP-1:2→TSP-1:8, CUB-1 and CUB-2 domains ............................. 35 1.4 ADAMTS13 cleavage of VWF ............................................................... 37 1.4.1 Factors affecting cleavage of VWF by ADAMTS13 ........................ 39 1.4.2 Disulphide bond reduction of VWF by ADAMTS13 ........................ 41 1.4.3 VWF and ADAMTS13 cleavage ....................................................... 42 1.5 Thrombotic thrombocytopenic purpura................................................... 42 5 1.5.1 Signs and symptoms .......................................................................... 42 1.5.2 Incidence ............................................................................................ 43 1.5.3 Pathophysiology ................................................................................. 44 1.5.4 Triggers:infection ............................................................................... 44 1.5.5 Triggers: Pregancy ............................................................................. 45 1.5.6 Treatment ........................................................................................... 45 1.6 Congenital TTP ....................................................................................... 46 1.6.1 ADAMTS13 mutations ....................................................................... 47 1.6.2 ADAMTS13 polymorphisms .............................................................. 47 1.6.3 Mouse models of congenital TTP ...................................................... 48 1.6.4 Residual ADAMTS13 activity ........................................................... 50 1.7 Acquired TTP .......................................................................................... 54 1.7.1 Baboon models of acquired TTP ....................................................... 55 1.8 New therapeutic options for TTP ............................................................ 55 1.9 ADAMTS13 deficiency in the setting of other diseases ......................... 59 1.10 ADAMTS13 genetic variation in diseases other than TTP ...................... 60 1.11 Aims of thesis .......................................................................................... 60 Chapter 2 Materials and methods ....................................................................... 61 2.1 In silico analysis of ADAMTS13 missense mutations ............................. 61 2.2 Creation of ADAMTS13 missense mutations .......................................... 62 2.2.1 Sequencing ADAMTS13 cDNA ......................................................... 62 2.2.2 Site directed mutagenesis ................................................................... 62 2.2.3 DpnI digestion and agarose gel electrophoresis................................. 63 2.2.4 Transformation ................................................................................... 63 2.2.5 Mini preparation................................................................................. 64 2.2.6 Sequencing of construct to confirm presence of mutation ................. 64 2.2.7 Large scale plasmid preparation ........................................................ 65 6 2.3 Transient transfection of ADAMTS13 variants ...................................... 66 2.3.1 HEK 293T cells.................................................................................. 66 2.3.2 Transient transfection......................................................................... 66 2.3.3 Normalisation after transient transfection .......................................... 67 2.3.4 Concentrating media .......................................................................... 68 2.4 Creation of stable lines ............................................................................ 68 2.5 Western blotting ...................................................................................... 69 2.6 ADAMTS13 antigen ELISA ................................................................... 70 2.6.1 In-house ADAMTS13 antigen ELISA............................................... 70 2.6.2 Commercial ADAMTS13 antigen ELISA ......................................... 71 2.7 ADAMTS13 activity assay: FRETS-VWF73 ........................................
Recommended publications
  • Role of Proteases in Dysfunctional Placental Vascular Remodelling in Preeclampsia

    Role of Proteases in Dysfunctional Placental Vascular Remodelling in Preeclampsia

    Accepted Manuscript Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez, Isabel Gómez, Delia I. Chiarello, Rocío Salsoso, Andrés D. Klein, Enrique Guzmán-Gutiérrez, Fernando Toledo, Luis Sobrevia PII: S0925-4439(19)30115-2 DOI: https://doi.org/10.1016/j.bbadis.2019.04.004 Reference: BBADIS 65448 To appear in: BBA - Molecular Basis of Disease Received date: 23 February 2018 Revised date: 20 December 2018 Accepted date: 6 January 2019 Please cite this article as: J.A. Gutiérrez, I. Gómez, D.I. Chiarello, et al., Role of proteases in dysfunctional placental vascular remodelling in preeclampsia, BBA - Molecular Basis of Disease, https://doi.org/10.1016/j.bbadis.2019.04.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Role of proteases in dysfunctional placental vascular remodelling in preeclampsia Jaime A. Gutiérrez1,7 *, Isabel Gómez1, Delia I Chiarello7, Rocío Salsoso5,7†, Andrés D Klein2, Enrique Guzmán-Gutiérrez3, Fernando Toledo4,7, Luis Sobrevia5,6,7 * 1 Cellular Signaling and Differentiation Laboratory (CSDL), School of Medical Technology, Health Sciences Faculty, Universidad San Sebastián, Santiago 7510157, Chile. 2 Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7590943, Chile.
  • And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

    And MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment

    International Journal of Molecular Sciences Review Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment Stephan Niland and Johannes A. Eble * Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany; [email protected] * Correspondence: [email protected] Abstract: The tumor microenvironment (TME) has become the focus of interest in cancer research and treatment. It includes the extracellular matrix (ECM) and ECM-modifying enzymes that are secreted by cancer and neighboring cells. The ECM serves both to anchor the tumor cells embedded in it and as a means of communication between the various cellular and non-cellular components of the TME. The cells of the TME modify their surrounding cancer-characteristic ECM. This in turn provides feedback to them via cellular receptors, thereby regulating, together with cytokines and exosomes, differentiation processes as well as tumor progression and spread. Matrix remodeling is accomplished by altering the repertoire of ECM components and by biophysical changes in stiffness and tension caused by ECM-crosslinking and ECM-degrading enzymes, in particular matrix metalloproteinases (MMPs). These can degrade ECM barriers or, by partial proteolysis, release soluble ECM fragments called matrikines, which influence cells inside and outside the TME. This review examines the changes in the ECM of the TME and the interaction between cells and the ECM, with a particular focus on MMPs. Keywords: tumor microenvironment; extracellular matrix; integrins; matrix metalloproteinases; matrikines Citation: Niland, S.; Eble, J.A. Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix 1. Introduction Interactions in the Tumor Microenvironment.
  • Human ADAM12 Quantikine ELISA

    Human ADAM12 Quantikine ELISA

    Quantikine® ELISA Human ADAM12 Immunoassay Catalog Number DAD120 For the quantitative determination of A Disintegrin And Metalloproteinase domain- containing protein 12 (ADAM12) concentrations in cell culture supernates, serum, plasma, and urine. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................3 PRECAUTIONS .........................................................................................................................................................................4
  • Quantikine® ELISA

    Quantikine® ELISA

    Quantikine® ELISA Human ADAMTS13 Immunoassay Catalog Number DADT130 For the quantitative determination of human A Disintegrin And Metalloproteinase with Thombospondin type 1 motif, 13 (ADAMTS13) concentrations in cell culture supernates, serum, and plasma. This package insert must be read in its entirety before using this product. For research use only. Not for use in diagnostic procedures. TABLE OF CONTENTS SECTION PAGE INTRODUCTION .....................................................................................................................................................................1 PRINCIPLE OF THE ASSAY ...................................................................................................................................................2 LIMITATIONS OF THE PROCEDURE .................................................................................................................................2 TECHNICAL HINTS .................................................................................................................................................................2 MATERIALS PROVIDED & STORAGE CONDITIONS ...................................................................................................3 OTHER SUPPLIES REQUIRED .............................................................................................................................................4 PRECAUTIONS .........................................................................................................................................................................4
  • Crystal Structures of the Noncatalytic Domains of ADAMTS13 Reveal Multiple Discontinuous Exosites for Von Willebrand Factor

    Crystal Structures of the Noncatalytic Domains of ADAMTS13 Reveal Multiple Discontinuous Exosites for Von Willebrand Factor

    Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor Masashi Akiyamaa,1, Soichi Takedaa,1,2, Koichi Kokamea, Junichi Takagib, and Toshiyuki Miyataa,2 aNational Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan; and bLaboratory of Protein Synthesis and Expression, Institute for Protein Research, Osaka University, Suita, Osaka 565-0871, Japan Edited by Philip W. Majerus, Washington University Medical School, St. Louis, MO, and approved September 16, 2009 (received for review August 27, 2009) ADAMTS13 specifically cleaves plasma von Willebrand factor (VWF) distribution of VWF multimers is important for normal hemo- and thereby controls VWF-mediated platelet thrombus formation. stasis, as large multimers are hemostatically more active than Severe deficiencies in ADAMTS13 can cause life-threatening throm- small multimers (3). Deficiencies in ADAMTS13 activity, caused botic thrombocytopenic purpura. Here, we determined 2 crystal either by genetic mutations in the ADAMTS13 gene or by structures of ADAMTS13-DTCS (residues 287–685), an exosite- acquired inhibitory autoantibodies directed against the AD- containing human ADAMTS13 fragment, at 2.6-Å and 2.8-Å reso- AMTS13 protein, results in the accumulation of UL-VWF in the lution. The structures revealed folding similarities between the plasma (8–11). The UL-VWF accumulation leads to the forma- disintegrin-like (D) domain and the N-terminal portion of the tion of disseminated platelet-rich microthrombi in the micro- cysteine-rich domain (designated the CA domain). The spacer (S) vasculature, which results in the life-threatening disease, throm- domain forms a globular functional unit with a 10-stranded botic thrombocytopenic purpura (TTP).
  • Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer

    Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer

    ANTICANCER RESEARCH 31: 3839-3842 (2011) Inhibition of Tumor Growth by Antibody to ADAMTS1 in Mouse Xenografts of Breast Cancer TOMOHIRO HIRANO1, KUNITAKA HIROSE2, KENICHI SAKURAI1, MAKOTO MAKISHIMA3, KENJI SASAKI4† and SADAO AMANO1 1Division of Breast and Endocrine Surgery, Department of Surgery, 3Division of Biochemistry, Department of Biomedical Sciences and 4Division of Plastic and Reconstructive Surgery, Department of Plastic and Reconstructive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan; 2Biomedical Research Laboratory, Kureha Chemical Industry Co., Ltd., Shinjuku-ku, Tokyo, Japan Abstract. Background: A disintegrin and metalloproteinase carcinoma and Lewis lung carcinoma cells (4). ADAMTS1 and with thrombospondin motifs-1 (ADAMTS1), a member of the matrix metalloproteinase-1 synergistically promote bone ADAMTS family of proteases, is involved in the shedding of metastasis of breast cancer cells by shedding epidermal growth epidermal growth factor (EGF)-like ligands such as factor (EGF)-like ligands, including heparin-binding EGF (HB- amphiregulin, which activate the EGF receptor. Since EGF), amphiregulin, and transforming growth factor α, from ADAMTS1 has been implicated in aggressive breast tumor cells, and subsequent activation of the EGF receptor carcinogenesis, we examined potential antitumor effects of (EGFR) (5). In human breast samples, ADAMTS1 mRNA is antibody to ADAMTS1 in a mouse model of breast cancer. expressed in non-neoplastic mammary tissues, predominantly in Materials and Methods: BALB/c female mice were inoculated stromal fibroblasts, and is significantly down-regulated in breast with syngenic 4T1 breast cancer cells and treated with anti- carcinomas (6). The erythroblastic leukemia viral oncogene ADAMTS1 antibody or control IgG. Tumor volume and weight homolog (ERBB) family of receptor tyrosine kinases, were evaluated.
  • Association of ADAM12 Gene Polymorphisms with Knee Osteoarthritis Susceptibility

    Association of ADAM12 Gene Polymorphisms with Knee Osteoarthritis Susceptibility

    www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2017 Association of ADAM12 gene polymorphisms with knee osteoarthritis susceptibility SUPPLEMENTARY MATERIALS REFERENCES candidate genes for the prevalence and progression of knee osteoarthritis. Arthritis Rheum. 2004;50:2497-2507. 1. Poonpet T, Tammachote R, Tammachote N, Kanitnate S, 11. Kerna I, Kisand K, Laitinen P, Tamm A, Tamm A. Honsawek S. Association between ADAM12 polymorphism Association of metallopeptidase domain 12 (ADAM12) and knee osteoarthritis in Thai population. Knee. gene polymorphisms and ADAM12 protein with the 2016;23:357-361. development of knee osteoarthritis. Osteoarthritis Cartilage. 2. Wang L, Guo L, Tian F, Hao R, Yang T. Analysis of single 2010;18. nucleotide polymorphisms within ADAM12 and risk of 12. Stark K, Straub RH, Blažičková S, Hengstenberg C, knee osteoarthritis in a Chinese Han population. Biomed Rovenský J. Genetics in neuroendocrine immunology: Res Int. 2015;2015:518643. implications for rheumatoid arthritis and osteoarthritis. Ann 3. Lou S, Zhao Z, Qian J, Zhao K, Wang R. Association N Y Acad Sci. 2010;1193. of single nucleotide polymorphisms in ADAM12 gene 13. Limer KL, Tosh K, Bujac SR, McConnell R, Doherty S, with susceptibility to kneeosteoarthritis: a case-control Nyberg F, Zhang W, Doherty M, Muir KR, Maciewicz study in a Chinese Han population. Int J Clin Exp Pathol. RA. Attempt to replicate published genetic associations 2014;7:5154-5159. in a large, well-defined osteoarthritis case-control 4. Kerna I, Kisand K, Tamm AE, Kumm J, Tamm AO. population (the GOAL study). Osteoarthritis Cartilage. Two single-nucleotide polymorphisms in ADAM12 2009;17:782-789. gene are associated with early and late radiographic 14.
  • Comparative Transcriptome Analysis of Embryo Invasion in the Mink Uterus

    Comparative Transcriptome Analysis of Embryo Invasion in the Mink Uterus

    Placenta 75 (2019) 16–22 Contents lists available at ScienceDirect Placenta journal homepage: www.elsevier.com/locate/placenta Comparative transcriptome analysis of embryo invasion in the mink uterus T ∗ Xinyan Caoa,b, , Chao Xua,b, Yufei Zhanga,b, Haijun Weia,b, Yong Liuc, Junguo Caoa,b, Weigang Zhaoa,b, Kun Baoa,b, Qiong Wua,b a Institute of Special Animal and Plant Sciences, Chinese Academy of Agricultural Sciences, Changchun, China b State Key Laboratory for Molecular Biology of Special Economic Animal and Plant Science, Chinese Academy of Agricultural Sciences, Changchun, China c Key Laboratory of Embryo Development and Reproductive Regulation of Anhui Province, College of Biological and Food Engineering, Fuyang Teachers College, Fuyang, China ABSTRACT Introduction: In mink, as many as 65% of embryos die during gestation. The causes and the mechanisms of embryonic mortality remain unclear. The purpose of our study was to examine global gene expression changes during embryo invasion in mink, and thereby to identify potential signaling pathways involved in implantation failure and early pregnancy loss. Methods: Illumina's next-generation sequencing technology (RNA-Seq) was used to analyze the differentially expressed genes (DEGs) in implantation (IMs) and inter- implantation sites (inter-IMs) of uterine tissue. Results: We identified a total of 606 DEGs, including 420 up- and 186 down-regulated genes in IMs compared to inter-IMs. Gene annotation analysis indicated multiple biological pathways to be significantly enriched for DEGs, including immune response, ECM complex, cytokine activity, chemokine activity andprotein binding. The KEGG pathway including cytokine-cytokine receptor interaction, Jak-STAT, TNF and the chemokine signaling pathway were the most enriched.
  • ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4

    ADAMTS13 and 15 Are Not Regulated by the Full Length and N‑Terminal Domain Forms of TIMP‑1, ‑2, ‑3 and ‑4

    BIOMEDICAL REPORTS 4: 73-78, 2016 ADAMTS13 and 15 are not regulated by the full length and N‑terminal domain forms of TIMP‑1, ‑2, ‑3 and ‑4 CENQI GUO, ANASTASIA TSIGKOU and MENG HUEE LEE Department of Biological Sciences, Xian Jiaotong-Liverpool University, Suzhou, Jiangsu 215123, P.R. China Received June 29, 2015; Accepted July 15, 2015 DOI: 10.3892/br.2015.535 Abstract. A disintegrin and metalloproteinase with thom- proteolysis activities associated with arthritis, morphogenesis, bospondin motifs (ADAMTS) 13 and 15 are secreted zinc angiogenesis and even ovulation [as reviewed previously (1,2)]. proteinases involved in the turnover of von Willebrand factor Also known as the VWF-cleaving protease, ADAMTS13 and cancer suppression. In the present study, ADAMTS13 is noted for its ability in cleaving and reducing the size of the and 15 were subjected to inhibition studies with the full-length ultra-large (UL) form of the VWF. Reduction in ADAMTS13 and N-terminal domain forms of tissue inhibitor of metallo- activity from either hereditary or acquired deficiency causes proteinases (TIMPs)-1 to -4. TIMPs have no ability to inhibit accumulation of UL-VWF multimers, platelet aggregation and the ADAMTS proteinases in the full-length or N-terminal arterial thrombosis that leads to fatal thrombotic thrombocy- domain form. While ADAMTS13 is also not sensitive to the topenic purpura [as reviewed previously (1,3)]. By contrast, hydroxamate inhibitors, batimastat and ilomastat, ADAMTS15 ADAMTS15 is a potential tumor suppressor. Only a limited app can be effectively inhibited by batimastat (Ki 299 nM). In number of in-depth investigations have been carried out on the conclusion, the present results indicate that TIMPs are not the enzyme; however, expression and profiling studies have shown regulators of these two ADAMTS proteinases.
  • ADAMTS Proteases in Vascular Biology

    ADAMTS Proteases in Vascular Biology

    Review MATBIO-1141; No. of pages: 8; 4C: 3, 6 ADAMTS proteases in vascular biology Juan Carlos Rodríguez-Manzaneque 1, Rubén Fernández-Rodríguez 1, Francisco Javier Rodríguez-Baena 1 and M. Luisa Iruela-Arispe 2 1 - GENYO, Centre for Genomics and Oncological Research, Pfizer, Universidad de Granada, Junta de Andalucía, 18016 Granada, Spain 2 - Department of Molecular, Cell, and Developmental Biology, Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA Correspondence to Juan Carlos Rodríguez-Manzaneque and M. Luisa Iruela-Arispe: J.C Rodríguez-Manzaneque is to be contacted at: GENYO, 15 PTS Granada - Avda. de la Ilustración 114, Granada 18016, Spain; M.L. Iruela-Arispe, Department of Molecular, Cell and Developmental Biology, UCLA, 615 Charles Young Drive East, Los Angeles, CA 90095, USA. [email protected]; [email protected] http://dx.doi.org/10.1016/j.matbio.2015.02.004 Edited by W.C. Parks and S. Apte Abstract ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) proteases comprise the most recently discovered branch of the extracellular metalloenzymes. Research during the last 15 years, uncovered their association with a variety of physiological and pathological processes including blood coagulation, tissue repair, fertility, arthritis and cancer. Importantly, a frequent feature of ADAMTS enzymes relates to their effects on vascular-related phenomena, including angiogenesis. Their specific roles in vascular biology have been clarified by information on their expression profiles and substrate specificity. Through their catalytic activity, ADAMTS proteases modify rather than degrade extracellular proteins. They predominantly target proteoglycans and glycoproteins abundant in the basement membrane, therefore their broad contributions to the vasculature should not come as a surprise.
  • Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin

    Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin

    The Journal of Neuroscience, March 22, 2017 • 37(12):3181–3191 • 3181 Cellular/Molecular Secreted Metalloproteinase ADAMTS-3 Inactivates Reelin Himari Ogino,1* Arisa Hisanaga,1* XTakao Kohno,1 Yuta Kondo,1 Kyoko Okumura,1 Takana Kamei,1 Tempei Sato,2 Hiroshi Asahara,2 Hitomi Tsuiji,1 Masaki Fukata,3 and Mitsuharu Hattori1 1Department of Biomedical Science, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan, 2Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, Japan, and 3Division of Membrane Physiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Aichi 444-8787, Japan The secreted glycoprotein Reelin regulates embryonic brain development and adult brain functions. It has been suggested that reduced Reelin activity contributes to the pathogenesis of several neuropsychiatric and neurodegenerative disorders, such as schizophrenia and Alzheimer’s disease; however, noninvasive methods that can upregulate Reelin activity in vivo have yet to be developed. We previously found that the proteolytic cleavage of Reelin within Reelin repeat 3 (N-t site) abolishes Reelin activity in vitro, but it remains controversial as to whether this effect occurs in vivo. Here we partially purified the enzyme that mediates the N-t cleavage of Reelin from the culture supernatant of cerebral cortical neurons. This enzyme was identified as a disintegrin and metalloproteinase with thrombospondin motifs-3 (ADAMTS-3). Recombinant ADAMTS-3 cleaved Reelin at the N-t site. ADAMTS-3 was expressed in excitatory neurons in the cerebral cortex and hippocampus.
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types

    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.